Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients.

Lee YM, Kim YH, Han DJ, Park SK, Park JS, Sung H, Hong HL, Kim T, Kim SH, Choi SH, Kim YS, Woo JH, Lee SO.

Transpl Infect Dis. 2014 Jun;16(3):397-402. doi: 10.1111/tid.12227. Epub 2014 May 9.

PMID:
24810355
2.

Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses.

Toupance O, Bouedjoro-Camus MC, Carquin J, Novella JL, Lavaud S, Wynckel A, Jolly D, Chanard J.

Transpl Int. 2000;13(6):413-9.

3.

Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome.

Watcharananan SP, Louhapanswat S, Chantratita W, Jirasiritham S, Sumethkul V.

Transplant Proc. 2012 Apr;44(3):701-5. doi: 10.1016/j.transproceed.2011.12.029.

PMID:
22483472
4.

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.

Huurman VA, Kalpoe JS, van de Linde P, Vaessen N, Ringers J, Kroes AC, Roep BO, De Fijter JW.

Diabetes Care. 2006 Apr;29(4):842-7.

PMID:
16567825
5.

Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.

Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, Sardana R, Lal N, Kumar A.

Liver Transpl. 2012 Dec;18(12):1448-55. doi: 10.1002/lt.23540.

6.

HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.

Varga M, Rajczy K, Telkes G, Hídvégi M, Péter A, Remport A, Korbonits M, Fazakas J, Toronyi E, Sárváry E, Kóbori L, Járay J.

Nephrol Dial Transplant. 2008 Aug;23(8):2673-8. doi: 10.1093/ndt/gfn111. Epub 2008 Mar 10.

PMID:
18332066
7.

Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation.

Gómez E, Laurés A, Baltar JM, Melón S, Díez B, de Oña M.

Transplant Proc. 2005 Nov;37(9):3760-3.

PMID:
16386530
8.

Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.

Kim T, Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, Sung H, Jung JH, Shin S, Kim YH, Kang YA, Lee YS, Lee JH, Lee JH, Lee KH, Park SK, Han DJ, Kim SH.

Korean J Intern Med. 2016 Sep;31(5):961-70. doi: 10.3904/kjim.2015.079. Epub 2016 Apr 8.

9.

Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients.

Meijers RW, Litjens NH, Hesselink DA, Langerak AW, Baan CC, Betjes MG.

Am J Transplant. 2015 Dec;15(12):3143-56. doi: 10.1111/ajt.13396. Epub 2015 Jul 24.

10.

Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?

Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.

Liver Transpl. 2005 Jun;11(6):700-4.

11.

Risk factors for cytomegalovirus infection and disease in renal transplant recipients: HLA-DR7 and triple therapy.

Kraat YJ, Christiaans MH, Nieman FH, van den Berg-Loonen PM, van Hooff JP, Bruggeman CA.

Transpl Int. 1994 Aug;7(5):362-7.

PMID:
7993574
13.

Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.

Fernández-Ruiz M, Arias M, Campistol JM, Navarro D, Gómez-Huertas E, Gómez-Márquez G, Díaz JM, Hernández D, Bernal-Blanco G, Cofan F, Jimeno L, Franco-Esteve A, González E, Moreso FJ, Gómez-Alamillo C, Mendiluce A, Luna-Huerta E, Aguado JM; OPERA Study Group.

Transpl Int. 2015 Sep;28(9):1042-54. doi: 10.1111/tri.12586. Epub 2015 Apr 23.

14.

Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.

Taherimahmoudi M, Ahmadi H, Baradaran N, Montaser-Kouhsari L, Salem S, Mehrsai A, Kalantar E, Jahani Y, Pourmand G.

Transplant Proc. 2009 Sep;41(7):2841-4. doi: 10.1016/j.transproceed.2009.07.027.

PMID:
19765452
15.

Hospitalizations for cytomegalovirus disease after renal transplantation in the United States.

Abbott KC, Hypolite IO, Viola R, Poropatich RK, Hshieh P, Cruess D, Hawkes CA, Agodoa LY.

Ann Epidemiol. 2002 Aug;12(6):402-9.

PMID:
12160599
16.

Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients.

Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A.

Transplantation. 1999 Jan 15;67(1):94-7.

PMID:
9921803
17.

Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.

Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.

Clin Transplant. 2013 Jul-Aug;27(4):503-9. doi: 10.1111/ctr.12138. Epub 2013 Jun 3.

PMID:
23731387
18.

Cytomegalovirus infection in renal transplant recipients: one center's experience.

Bal Z, Uyar ME, Tutal E, Erdogan E, Colak T, Sezer S, Haberal M.

Transplant Proc. 2013;45(10):3520-3. doi: 10.1016/j.transproceed.2013.08.098.

PMID:
24314948
19.

[Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].

Varga M, Remport A, Czebe K, Péter A, Toronyi E, Sárváry E, Fehérvári I, Sulyok B, Járay J.

Orv Hetil. 2008 Mar 23;149(12):551-8. doi: 10.1556/OH.2008.28324. Review. Hungarian.

PMID:
18343771
20.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259

Supplemental Content

Support Center